Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To determine the auxological response to recombinant human growth hormone (rhGH) therapy in children with growth hormone deficiency (GHD) presenting at the National Institute of Child Health, Karachi, Pakistan.

Why It Was Studied

Short stature, Growth hormone deficiency, Recombinant human growth hormone.

Who Took Part

The age groups tagged for this paper are young children and children, both men and women.

Place and Duration of the Study: Department of Paediatric Endocrinology, National Institute of Child Health, Karachi, Pakistan, from January 2022 to December 2023.

All pre-pubertal children with short stature aged 3-12 years diagnosed with GHD and who were prescribed rhGH therapy were included in the study.

How the Study Was Run

Children with any other underlying reason for short stature or any other comorbidity were excluded.

Patients' demographics and baseline growth parameters were recorded in a pre-designed proforma.

Patients were then followed up every three months till one year.

What Was Measured

PubMed files the paper under topics including Human Growth Hormone, Body Height, Recombinant Proteins, Growth Disorders, Pakistan and Dwarfism, Pituitary.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Journal of the College of Physicians and Surgeons--Pakistan : JCPSP), a journal based in Pakistan.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.